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Abstract
Background: Intermittent preventive treatment of malaria with sulphadoxine-pyrimethamine (SP) is recommended
for the prevention of malaria in pregnancy in sub-Saharan Africa. Increasing drug resistance necessitates the urgent
evaluation of alternative drugs. Currently, the most promising candidates in clinical development are mefloquine
and azithromycin. Besides the anti-malarial activity, SP is also a potent antibiotic and incurs significant anti-
microbial activity when given as IPTp - though systematic clinical evaluation of this action is still lacking.
Methods: In this study, the intrinsic anti-bacterial activity of mefloquine and azithromycin was assessed in
comparison to sulphadoxine-pyrimethamine against bacterial pathogens with clinical importance in pregnancy in a
standard microdilution assay.
Results: SP was highly active against Staphylococcus aureus and Streptococcus pneumoniae. All tested Gram-positive
bacteria, except Enterococcus faecalis, were sensitive to azithromycin. Additionally, azithromycin was active against
Neisseria gonorrhoeae. Mefloquine showed good activity against pneumococci but lower in vitro action against all
other tested pathogens.
Conclusion: These data indicate important differences in the spectrum of anti-bacterial activity for the evaluated
anti-malarial drugs. Given the large scale use of IPTp in Africa, the need for prospective clinical trials evaluating the
impact of antibiotic activity of anti-malarials on maternal and foetal health and on the risk of promoting specific
drug resistance of bacterial pathogens is discussed.
Background
Malaria in pregnancy is associated with low birth-weight
[1-3], pre-term delivery [4] and maternal anaemia [5]
and is therefore an important cause of maternal, perina-
tal, and neonatal morbidity and mortality in pregnancy
and the puerperium in sub-Saharan Africa [6,7]. The
World Health Organization recommends intermittent
preventive treatment of malaria in pregnancy with sul-
phadoxine-pyrimethamine (SP-IPTp) in order to reduce
adverse health outcomes for pregnant women and their
offspring [8,9]. Curative doses of SP are administered
during routine antenatal visits at least twice after the
first trimester in HIV negative and at least three times
in HIV positive women. Due to rising drug resistance of
Plasmodium falciparum against SP, potential alternative
anti-malarial drugs have been proposed for future use as
IPTp [10]. These compounds include amodiaquine, azi-
thromycin, mefloquine, and combinations of these drugs
with artemisinin derivatives or chloroquine [11,12].
Bacterial infections including sexually transmitted dis-
eases, urinary tract infections, and group B streptococcal
carriage are causes for considerable morbidity and mor-
tality in pregnant women and the unborn child. In sub-
Saharan Africa adequate diagnosis and treatment of these
infections are often lacking. SP belongs to the class of
anti-folates exerting considerable anti-microbial activity
besides its anti-malarial activity. Anti-folate antibiotics
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any medium, provided the original work is properly cited.show clinically important activity against Streptococcus
pneumoniae, Staphylococcus aureus, Escherichia coli, and
other pathogenic bacteria and are, therefore, used on a
large scale for the treatment of urinary tract infections,
skin and soft tissue infections, and in other indications
[13,14]. Whereas mefloquine use is currently restricted to
treating falciparum malaria, azithromycin is in use for the
treatment of a variety of bacterial infections including
respiratory tract infections and sexually transmitted
diseases and it is under investigation for combination
therapy of falciparum malaria [15,16].
IPTp with a drug exerting anti-bacterial activity may,
therefore, offer a significant additional public health
benefit by providing treatment for undetected or pre-
viously untreated bacterial infections in pregnant
women. Conversely, widespread use of antibiotics may
increase the risk for the development of drug resistance
leading to future difficulties in the clinical management
of bacterial infections.
This study aimed to assess the anti-bacterial activity of
SP, mefloquine and azithromycin - the most promising
candidate drugs for the replacement of SP for IPTp [15] -
against common Gram-positive and Gram-negative
bacteria in vitro.
Methods
The minimal inhibitory concentrations (MIC) of meflo-
quine, azithromycin, and SP was assessed against bacter-
ial pathogens with medical importance during pregnancy.
For this purpose, common bacterial pathogens causing
urinary tract infections (Escherichia coli, Enterococcus
faecalis), sexually transmitted diseases (Neisseria gonor-
rhoeae), skin and soft tissue infections (Staphylococcus
aureus) and neonatal sepsis (Group B beta-haemolytic
streptococci; i.e. Streptococcus agalactiae) were studied.
Tested microorganisms consisted of clinical isolates and
American Type Culture Collection (ATCC) strains as
external controls. Bacteria were grown overnight at 37°C
in Mueller Hinton broth with or without 2-5% horse-
blood. Neisseria gonorrhoeae was incubated overnight at
35°C in an atmosphere containing 5% CO2 on New York
City agar and chocolate agar.
All drugs were obtained from Sigma-Aldrich (Seelze,
Germany) and were first dissolved and diluted to stock
solutions. Further 1:2 dilutions of stock solutions were
done with culture medium in order to achieve respective
drug concentrations. Mueller Hinton broth medium
was commercially prepared (Merck KGaA, Darmstadt,
Germany). Fastidious broth medium was used for cultiva-
tion of N. gonorrhoeae and was prepared as described pre-
viously consisting of 35 g Columbia broth base, 5 g
glucose, 5 g yeast extract, 2 g neopeptone, and 0.75 g agar-
ose dissolved in 960 ml of distilled water [17]. A total of
30 ml haematin solution (0.05% [wt/vol] in 0.1 M NaOH)
and 5 ml Tween 80 (10% [vol/vol]) was then added. The
resultant broth was sterilized by autoclaving and 6 ml of
pyridoxal solution (0.1% [wt/vol]) and 1.5 ml of NAD solu-
tion (1% wt/vol) were added.
Determination of MICs
MICs were determined by employing a standard microdi-
lution assay following Clinical and Laboratory Standards
Institute (CLSI) guidelines with fastidious broth medium
and Mueller Hinton broth and a bacterial turbidity of
0.5 McFarland. The final bacterial density was approxi-
mately 10
5 CFU/ml. The 96-well plates were incubated
for 24 h at 35°C in a moist atmosphere containing 5%
CO2. Positive control wells contained microorganisms
without antibiotics. All tests were performed in duplicate
and MICs were reported as arithmetic means.
Classifiction of anti-bacterial activity
CLSI consensus cut off levels were used for the categoriza-
tion of anti-bacterial activity. Azithromycin susceptibility
was assessed using the following cut off levels for classifi-
cation as sensitive, intermediate and resistant: S. aureus ≤2
μg/ml, >2 - <8 μg/ml, ≥8 μg/ml; S. pneumonia and S.
agalactiae ≤0.5 μg/ml, >0.5 - <2 μg/ml, ≥ 2 μg/ml. In
case of N. gonorrhoeae, due to a lack of CLSI recom-
mendations, the European committee on anti-microbial
susceptibility testing (EUCAST) definitions for azithro-
mycin cut-off values (≤ 0.25 μg/ml; > 0.25 μg/ml - ≤
0.5 μg/ml; > 0.5 μg/ml as sensitive, intermediate, resis-
tant) were employed.
No break points are defined for the activity of azi-
thromycin against E. coli and Enterococcus by CLSI
and EUCAST. Cut off levels as proposed for S. aureus
(≤2 μg/ml, >2 - <8 μg/ml, ≥ 8 μg/ml for susceptible,
intermediate and resistant, respectively) were therefore
used.
No recommendations are available for mefloquine
and SP by CLSI or EUCAST and no previous publica-
tions on the interpretation of in vitro anti-bacterial
activity of the two anti-malarial drugs were found. For
the classification of SP activity - due to comparable
anti-bacterial pharmacodynamics in the class of anti-
folate antibiotics and similar molecular weights for
trimethoprim and pyrimethamine (290 and 249,
respectively) - CLSI and EUCAST threshold levels of
anti-bacterial activity were used as defined for tri-
methoprim-sulphamethoxazole. These definitions are
based on trimethoprim drug concentrations and were
employed for pyrimethamine to classify SP activity.
The CLSI cut off levels for classification as sensitive,
intermediate and resistant are the following: S. aureus
and E.coli: ≤ 2 μg/ml; > 2 - < 4 μg/ml; ≥ 4 μg/ml,
S. pneumonia: ≤ 0.5 μg/ml; > 0.5 - < 4 μg/ml; ≥ 4 μg/
ml. The EUCAST cut off levels: S. agalactiae: ≤ 1 μg/
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ml; ≥ 0.03 μg/ml - ≤ 1 μg/ml, > 1 μg/ml. For meflo-
quine the threshold of drug resistance was set consid-
ering available pharmacokinetic data in human patients
and published in vitro inhibitory concentrations against
Plasmodium falciparum [18-24]. Thus, the threshold
for drug resistance was 0.265 μg/ml for mefloquine.
Results
All bacterial isolates were sub-cultured after thawing prior
to susceptibility assays (n = 34). Median MIC values of SP
against Gram-positive bacteria were as follows: S. aureus
16 μg/ml, S. agalactiae 24 μg/ml, S. pneumoniae 4 μg/ml,
and E. faecalis 12 μg/ml (Table 1, Table 2 and Additional
File 1). Median MICs were considerably higher for
N. gonorrhoeae and E. coli (256 μg/ml and 128 μg/ml,
respectively). SP showed high or intermediate activity
against all tested Gram-positive bacteria, whereas E. coli
and N. gonorrhoeae were classified as resistant to SP.
A total of 34 bacterial isolates were evaluated for their
in vitro drug susceptibility against mefloquine (Table 1,
Table 2 and Additional File 1). The observed MIC of
mefloquine was 16 μg/ml in all tested S. aureus and
E. faecalis isolates. Similarly growth of S. agalactiae was
completely inhibited at 16 μg/ml except for one isolate
with a MIC of 32 μg/ml. The MIC of mefloquine against
pneumococci and N. gonorrhoeae varied between 0.03 -
0.06 μg/ml and 4 - 16 μg/ml, respectively. Based on the
observed MIC values S. pneumonia was classified as
sensitive, S. aureus, S. agalactiae, E. faecalis,a n d
N. gonorrhoeae,a n dE. coli (Median MIC 128 μg/ml) as
resistant to the in vitro activity of mefloquine.
Median MIC values of azithromycin were 0.5 μg/ml,
0.06 μg/ml, 0.01 μg/ml and 0.01 μg/ml against S. aureus,
S. agalactiae, S. pneumonia, and N. gonorrhoeae, respec-
tively (Table 1, Table 2 and Additional File 1). Activity
against E. coli (median MIC 4 μg/ml) and E. faecalis
(median MIC 4 mg/ml) was considerably weaker. Neis-
seria gonorrhoeae and all Gram-positive bacteria -
except for E. faecalis -were classified as being sensitive
to azithromycin. Escherichia coli strains showed inter-
mediate drug susceptibility against azithromycin in vitro.
Discussion
This in vitro drug susceptibility study showed a broad
spectrum of anti-bacterial activity of SP against Gram-
positive and low activity against Gram-negative bacteria.
Among the two currently proposed alternative drugs for
IPTp - mefloquine and azithromycin - the latter shows
Table 1 Median minimal inhibitory concentrations (MIC) of anti-malarials against selected Gram-positive and Gram-
negative bacteria
Microorganisms Median Minimal Inhibitory Concentration (μg/ml)
Sulphadoxine/Pyrimethamine Mefloquine Azithromycin
S. aureus (n = 5) 16 16 0.5
S. agalactiae (n = 4) 24 16 0.06
S. pneumoniae (n = 5) 4 0.06 0.01
E. faecalis (n = 5) 12 16 4
N. gonorrhoeae (n = 10) 256 8 0.01
E. coli (n = 5) 128 128 4
Thresholds for drug resistance:
Mefloquine: sensitive: ≤ 0.265 μg/ml
Sulphadoxine/Pyrimethamine (threshold based on fractional pyrimethamine concentration in 1:20 combination): sensitive, intermediate, resistant
S. aureus and E. coli: ≤2 μg/ml; >2 - <4 μg/ml; ≥4 μg/ml,
S. pneumonia: ≤0.5 μg/ml; >0.5 - <4 μg/ml; ≥4 μg/ml,
S. agalactiae: ≤1 μg/ml; >1 - ≤2 μg/ml; >2 μg/ml,
E. faecalis: ˂0.03 μg/ml; ≥ 0.03 - ≤ 1 μg/ml; > 1 μg/ml.
Azithromycin: sensitive, intermediate, resistant
S. aureus; E. coli and E. faecalis ≤2 μg/ml, >2 - <8 μg/ml, ≥8 μg/ml;
S. pneumonia and S. agalactiae ≤0.5 μg/ml, >0.5 - <2 μg/ml, ≥2 μg/ml;
N. gonorrhoeae ≤0.25 μg/ml; >0.25 μg/ml - ≤0.5 μg/ml; >0.5 μg/ml;
Table 2 Summary of in vitro anti-bacterial activity of
sulphadoxine-pyrimethamine, mefloquine, and
azithromycin
Sulphadoxine/
Pyrimethamine
Mefloquine Azithromycin
S. aureus +- +
S. agalactiae ~- +
S. pneumoniae ++ +
E. faecalis ~ - ~/-
N. gonorrhoeae -- +
E. coli -- ~
- Insufficient in vitro activity; ~ intermediate in vitro activity; + good in vitro
activity.
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with good activity against N. gonorrhoeae. Interestingly,
previous reports indicate in vitro activity of mefloquine
against E. coli [25,26]. The present study, however,
demonstrated high activity of mefloquine against pneu-
mococci and low activity against all other bacteria.
Whether these findings similarly translate into clinically
relevant in vivo activity of mefloquine needs further
investigation since no validated resistance thresholds are
available for mefloquine.
This evaluation of the anti-microbial activity of anti-
malarials in vitro may provide the basis for further clini-
cal evaluation. Based on our data a clinically important
effect on concurrent infectious diseases in pregnant
women may be anticipated for SP and azithromycin and
to a lesser extent for mefloquine. Previous data show that
bacterial infections including sexually transmitted dis-
eases, pneumococcal infections, and S. agalactiae coloni-
sation contribute significantly to adverse pregnancy
outcome in sub-Saharan Africa [27]. Similarly, there is
evidence for significant improvement of maternal and
child health by routine administration of appropriate
anti-microbial drugs during pregnancy [28]. Given that
urinary and genital tract infections are an important
cause for premature delivery, it may be speculated that
the routine administration of SP and azithromycin for
IPTp may confer a reduction in the rate of prematurity
due to the antibiotic effect. Similarly the potential for era-
dication of vaginal S. agalactiae colonization by IPTp
with SP or azithromycin might prevent cases of neonatal
sepsis. However, caution must be employed by the extra-
polation of data on in vitro activity of drugs to antici-
pated in vivo efficacy. Clinical efficacy will ultimately
depend - besides the intrinsic anti-bacterial activity as
assessed in this study - on drug absorption, drug concen-
trations at the target sites, half-lives of drugs, and the
local pattern of drug resistant pathogens. Additionally a
limitation of our study lies in the absence of validated
thresholds for the in vitro activity of SP and mefloquine.
The proposed levels are extrapolated from antifolate anti-
biotics or based on thresholds of in vitro activity against
P. falciparum and need further clinical validation [17].
The next generation of IPTp drugs will be chosen
based on pharmacodynamic properties and its safety,
tolerability, simplicity of administration, and cost. Based
on the hypothesis of a collateral health benefit by the
administration of anti-malarials with activity against
relevant bacterial pathogens, it may seem desirable
to choose the next IPTp drug based on both its anti-
malarial and anti-bacterial pharmacodynamic properties.
Whether such an approach is justified or not is however
to date unknown. Whereas it may look attractive to
simultaneously treat concomitant and potentially dele-
terious bacterial infections by routine administration of
anti-malarials, this strategy may also prove hazardous.
Large-scale use of drugs with anti-bacterial activity may
speed up the process of selection of drug resistant bac-
terial isolates. Interestingly, there is evidence for
the development of antibiotic drug resistance by cross-
resistance with anti-malarial drugs [29]. Epidemiologic
evidence linking the development of quinolone resistant
Gram-negative bacteria with large-scale use of chloro-
quine and the recent development and spread of quino-
lone resistant N. gonorrhoeae strains are illustrative
examples for this phenomenon [30]. In this context the
potential selection of drug resistance against anti-folate
and macrolide antibiotics by the use of SP and azithro-
mycin as IPTp is of particular concern. The threat of
promoting drug resistance against commonly used anti-
biotics is particularly worrying for sub-Saharan Africa
where microbiologic analysis of infections is rarely per-
formed and alternative antibiotics for drug resistant
pathogens are often not affordable.
Conclusion
T h e s ed a t ai n d i c a t et h a ts u l phadoxine-pyrimethamine
and azithromycin are active against a broad spectrum of
bacterial pathogens whereas mefloquine’sa c t i v i t yi s
restricted to pneumococci. Whether the choice of a sec-
ond generation IPTp drug with broad or narrow anti-
bacterial spectrum is favourable for maternal and foetal
health, is currently unknown. Further clinical trials eval-
uating the efficacy of IPTp against concomitant bacterial
infections and the impact of their large scale use on the
development and spread of antibiotic drug resistance are
therefore necessary to allow an informed decision on the
next IPTp drug for Africa.
Additional material
Additional file 1: Minimal inhibitory concentrations (MIC) of anti-
malarials against selected Gram positive and Gram negative
bacteria. Listing of minimal inhibitory concentrations of all isolates.
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